Friday - July 03, 2026

Category Archives: Science

Colorectal Cancer Pipeline Expands as 195+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2026” report provides comprehensive insights about 195+ companies and 200+ pipeline drugs in Colorectal Cancer pipeline landscape. It covers the Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Herpes Zoster Therapeutics Market Size (7MM) is projected to grow at a significant CAGR by 2036, estimates DelveInsight

DelveInsight’s “Herpes Zoster Market Insights, Epidemiology, and Market Forecast-2036” report delivers an in-depth understanding of the Herpes Zoster, historical and forecasted epidemiology as well as the Herpes Zoster market trends in the United States, EU5 (Germany, Spain, Italy, France, and … Continue reading →

Wet Age-related Macular Degeneration (Wet AMD) Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight

As per DelveInsight’s assessment, globally, the Wet Age-related Macular Degeneration (Wet AMD) pipeline constitutes several key companies continuously working towards developing Wet AMD treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. … Continue reading →

Congenital Hyperinsulinism Pipeline Expands as 4+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Congenital Hyperinsulinism Pipeline Insight 2026” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Congenital Hyperinsulinism pipeline landscape. It covers the Congenital Hyperinsulinism pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Chronic Urticaria Pipeline Expands as 20+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Chronic Urticaria Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Chronic Urticaria pipeline landscape. It covers the Chronic Urticaria pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Cutaneous Lupus Erythematous Pipeline Expands as 10+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Cutaneous Lupus Erythematosus Pipeline Insight 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Cutaneous Lupus Erythematosus pipeline landscape. It covers the Cutaneous Lupus Erythematosus Pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Bladder Cancer Pipeline Expands as 80+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Bladder Cancer Pipeline Insight 2026” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Bladder cancer pipeline landscape. It covers the Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

HPV+ Oropharyngeal Cancer Market is Projected to Witness Significant Growth by 2036 Owing to the Emergence of Novel Immunotherapies and Therapeutic Vaccines | DelveInsight

The market dynamics for HPV+ Oropharyngeal Cancer are witnessing significant growth driven by the rising incidence of HPV-associated head and neck cancers, increasing adoption of immunotherapy, expanding use of checkpoint inhibitors, and the development of novel therapeutic vaccines and targeted … Continue reading →

PSMA-Targeted Therapies Market is Projected to Witness Significant Growth by 2036 Owing to the Launch of Next-Generation Radioligand Therapies | DelveInsight

The market dynamics for PSMA-Targeted Therapies are witnessing significant growth driven by the increasing prevalence of prostate cancer, rising adoption of precision oncology, growing demand for targeted radioligand therapies, and expanding clinical development of next-generation PSMA-directed therapeutics. Additionally, the launch … Continue reading →